Document is current

Article History

Accepted: 4 June 2021

First Online: 12 July 2021

Declarations

:

: This study was sponsored by Pfizer Inc.

: C. Mamolo and J.C. Cappelleri are employees and shareholders of Pfizer Inc. B. Muresan and B. Heeg are employees of Ingress-Health BV, and were paid consultants to Pfizer in connection with the development of this article, which provides consulting and other research services to pharmaceutical, medical device, and related organizations. In their salaried positions, they work with a variety of companies and organizations, and are precluded from receiving payment or honoraria directly from these organizations for services rendered. B. Heeg is also an equity holder of Ingress-Health. M.J. Postma received grants and honoraria from various pharmaceutical companies, including those developing, producing, and marketing the drugs included in this paper. Also, M.J. Postma is advisor to Asc Academics and holds stocks in Pharmacoeconomics Advice Groningen, Health-Ecore and Ingress-Health; the latter company was paid by Pfizer Inc. to conduct this study and develop this article.

: Not applicable.

: Not applicable.

: Visual Basic code used for PSA and DSA programming is available on request.

: Conception and design of the work—BM, CM, JCC, BH; acquisition and analysis of the data—BM, CM, JCC, BH; interpretation of the data—BM, CM, JCC, MJP, BH; drafting the work and revising it for important intellectual content—BM, CM, JCC, MJP, BH; final approvals for publication and agreement to be accountable for all aspects of the work—BM, CM, JCC, MJP, BH.

: Available on request (stored on password-protected external hard drives).